Recognized for pioneering AI-driven innovation, customer-centric digital transformation, and customer experience for CSPs.

SAN ANTONIO, Dec. 5, 2025 /PRNewswire/ — Frost & Sullivan is pleased to announce that Whale Cloud has been recognized with the 2025 Asia-Pacific Technology Innovation Leadership Recognition in the AI-enabled OSS/BSS industry for its outstanding achievements in innovation, platform integration, and customer impact. This recognition highlights Whale Cloud’s consistent leadership in driving measurable outcomes, strengthening its market position, and delivering AI innovation and customer-centric digital transformation. With AI increasingly driving solutions for customers, the company has proactively pre-empted some key challenges to ensure customers seamlessly benefit from use of AI.

Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: business impact and strategic technology leverage. Whale Cloud excelled in both, demonstrating its ability to align strategic initiatives with market demand while executing them with efficiency, consistency, and scale.

“Whale Cloud is well positioned to ride out a growth trajectory over the next three to five years. WhaleDI AI will do well in growing the use of AI orchestration within mobile services and other vertical industries,” said Mei Lee Quah, Senior Director, ICT Research at Frost & Sullivan.

Guided by a long-term growth strategy centered on AI innovation, ecosystem partnerships, and customer success, Whale Cloud continues to lead in delivering end to end digital transformation across the Asia-Pacific region. Founded in 2003 and formerly known as ZTEsoft, the company has been building its big data and AI capabilities for many years. Today, Whale Cloud delivers cutting-edge OSS/BSS, cloud, big data, and AI-integrated solutions to communications service providers (CSPs), government agencies, and enterprises in over 80 countries. Its 19 global capability centers, including two dedicated to AI research and development, ensure sustained innovation and operational excellence.

Innovation remains central to Whale Cloud’s approach. Its flagship WhaleDI AI platform exemplifies its customer-centric commitment, enabling automation, personalization, and operational intelligence across diverse industries. The platform addresses critical challenges such as fragmented data, slow service rollout, and limited personalization by integrating multimodal AI for predictive, generative, and preceptive decision-making. Strategically embedded across Whale Cloud’s core offerings—including the ZSmart Digital OSS/BSS suite, cloud solutions, and smart city platforms—WhaleDI AI enhances automation, optimizes customer journeys, and drives real-time intelligence at scale. The end-to-end integration of WhaleDI AI across platforms enables customers to leverage AI as embedded AI capabilities across all layers.

“This recognition reflects our long-term commitment to advancing AI-driven innovation across telecom operations. By embedding intelligence into our ZSmart Digital OSS/BSS solutions, we aim to help CSPs simplify complexity, enhance agility, and accelerate digital transformation. This award is a testament to the dedication of our teams and the trust of our customers and partners,” said Steven Cho, CMO of Whale Cloud International.

Whale Cloud’s ZSmart Digital OSS/BSS suite supports modular deployment, AI-driven orchestration, and predictive maintenance to deliver improved operational efficiency and reduced total cost of ownership (TCO) for CSPs. Complementary solutions, including Digital Marketing Cloud (DMC), Fiber as a Service (FaaS), and Intelligent Network & Service Operation Center (iNOC), extend AI-driven capabilities to customer engagement, fiber deployment, and network operations. Through strong partnerships with Alibaba Cloud, ZTE, and selected ecosystem including with Alipay+ Payment Tech, Whale Cloud continues to accelerate digital transformation services, and smart city initiatives across emerging markets in Asia-Pacific, Africa, and Latin America.

Frost & Sullivan commends Whale Cloud for setting a high standard in competitive strategy, technology innovation, and execution excellence. The company’s vision, robust innovation pipeline, and customer-first culture are shaping the future of AI-enabled OSS/BSS and driving measurable results for service providers and enterprises worldwide.

Each year, Frost & Sullivan presents the Technology Innovation Leadership Recognition to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. The recognition honors forward-thinking organizations that are redefining their industries through technological innovation and growth excellence.

Frost & Sullivan Best Practices Recognition

Frost & Sullivan’s Best Practices Recognitions honor companies across regional and global markets that exhibit exceptional achievement and consistent excellence in areas such as leadership, technological innovation, customer experience, and strategic product development. Each recognition is the result of a rigorous analytical process in which Frost & Sullivan industry experts benchmark performance through comprehensive interviews, deep-dive analysis, and extensive secondary research. The goal is to identify true best-in-class organizations that are driving transformative growth and setting new industry standards.
Contact us: Start the discussion.

Contact:
Ashley Shreve
E: ashley.weinkauf@frost.com 

About Whale Cloud
Whale Cloud is a leading technology company that specializes in the digital transformation of telecommunication service providers and other verticals. We provide mission-critical solutions and services in Telecom, FinTech, and E&G sectors. At Whale Cloud, we’re passionate about creating frictionless experiences for customers and empowering their digital ambitions.

Contact:
Xu Dong
E: dong.xu51@iwhalecloud.com

SHANGHAI, Dec. 5, 2025 /PRNewswire/ — OTR Therapeutics, a biotechnology company dedicated to transforming early-stage innovations into globally impactful therapies, emerged from stealth and announced today the successful completion of a $100 million Series A financing closed in June 2025. The round was backed by True Light Capital, a wholly-owned subsidiary of Temasek, LAV, Pfizer Ventures, and Sirona Capital.

Founded in March 2025, OTR Therapeutics is establishing a novel, scalable, and capital-efficient model that synergizes internal R&D with strategic curation of high-potential external innovation. This integrated approach enables the company to focus on scientific rigor and operational agility, leveraging its deep regional insights and the development efficiency of the local ecosystem to accelerate innovative therapies to patients worldwide.

The proceeds of the financing will advance OTR’s pipeline of differentiated programs that target significant treatment gaps in immunology & inflammation, oncology, and other disease areas. The funds will also expand OTR’s R&D hub capability, which emphasizes both scientific excellence and strategic partnership agility to foster expedited development of high-impact therapies.

In line with its strategy, OTR also announced the acquisition of a preclinical program with best-in-class potential for neurological diseases with high unmet needs. This acquisition is part of the company’s strategic and ongoing efforts to identify and advance promising early-stage assets into global clinical development, alongside its internal proprietary discovery programs to address a broader range of critical patient needs.

“The rapidly evolving global pharmaceutical R&D landscape demands greater novelty, speed and efficiency,” said Dr. Zhui Chen, Founder and CEO of OTR Therapeutics. “At OTR, we aim to build a next-generation biotech model that delivers unprecedented R&D and capital efficiency. It enables us to stay agile while remaining rigorously focused on propelling novel, differentiated drug candidates through global clinical translation in a disciplined and efficient manner. We are grateful for the strong support from our investors and their confidence in our vision and capability to deliver transformative therapies for patients.”

Co-founded by Zhui Chen, Ph.D., Shannon Chuai, Ph.D., and Yuan Shi, Ph.D., OTR Therapeutics is led by a team of seasoned drug hunters and entrepreneurs in the biotech and pharmaceutical industries with a proven track record of delivering breakthrough innovation, operational excellence, and financial success.

Yi Shi, Managing Director, LAV: “We believe the biopharma industry is shifting towards more capital-efficient and specialized R&D models. OTR Therapeutics is at the forefront of this evolution, demonstrating how a focused, integrated framework can expedite the journey of translating early-stage innovation into global clinical development.”

Michael Baran, Partner, Pfizer Ventures: “Pfizer Ventures identifies and invests in emerging companies who are developing innovative medicines and technologies that have the potential to shape the future of our industry. To this end, we’re pleased to be able to support OTR Therapeutics as it scales its R&D capabilities and builds a portfolio of potentially transformative therapies.”

About True Light
True Light (Shanghai) Private Equity invests in innovative, high-growth businesses in Greater China. It is a subsidiary of True Light Capital and is registered with the Asset Management Association of China. True Light Capital is an asset manager headquartered in Singapore and currently has assets under management of ~US$4b from global investors. It manages funds that are focused on investing in high-quality investment opportunities which have a nexus to or have a major business relationship with Greater China. True Light Capital and True Light (Shanghai) Private Equity are independent, wholly-owned subsidiaries of Temasek (www.temasek.com.sg). For more information on True Light, please visit: www.truelightcap.com.

About OTR Therapeutics
OTR Therapeutics is a biotechnology company dedicated to transforming early-stage innovations into globally impactful therapies for critical diseases with high unmet medical needs. With a strategic focus on oncology, immunology and inflammation, and cardiometabolic diseases, we discover and acquire distinctive assets in preclinical and early clinical stages, and accelerate their development into differentiated, clinically impactful treatments through our R&D hub built for speed, quality and efficiency. By combining scientific rigor with agile partnerships, we deliver exceptional value to our partners and patients worldwide. From our advanced R&D center in Shanghai’s Zhangjiang Hi-Tech Park, we actively collaborate with a global network of partners across the US, Europe, and Asia. www.otr-tx.com

Longstanding Strategic Partnership Expands into Consumer Products and the Growing “Lobby Economy”

SHANGHAI, Dec. 5, 2025 /PRNewswire/ — IMAX Corporation (NYSE: IMAX), IMAX China Holding, Inc. (HKEX: 1970) and Wanda Film Holding Co., Ltd. (SZSE: 002739), China’s largest cinema operator, today announced the signing of a memorandum of understanding (MOU) to deepen their strategic partnership in merchandise development and IP initiatives. The agreement underscores the companies’ strategic alignment towards the structural shift underway in China’s film market and their shared commitment to developing the broader, cinema-driven consumer ecosystem emerging beyond the box office.

With this MOU, Wanda Film and IMAX will collaborate on merchandise development, brand-driven IP initiatives and retail programs, leveraging their extensive nationwide networks as sales channels to reach wider audiences. The two partners will work to create new revenue streams by tapping into the growing “lobby economy” and expanding incremental consumer engagement beyond the traditional box-office business. By combining the partners’ brand influence, content resources and distribution reach, this collaboration is poised to effectively tap into the growing momentum behind cinema-driven retail innovation in the market.

The announcement was made during IMAX’s Investor Day and follows a series of IMAX’s box-office milestones across the China market, fueled by the strong performances of “Demon Slayer: Infinity Castle” and “Zootopia 2”. The MOU also marks the second major expansion of the IMAX–Wanda Film partnership this year, following Wanda Film’s announcement in June that it will convert up to 27 premium-format auditoriums to IMAX systems. This continued momentum reflects Wanda Film’s confidence in IMAX’s brand equity and the growing commercial potential of China’s premium cinema sector, at a time when rising demand for film-inspired and culturally expressive consumer products is accelerating opportunities for new ancillary business models across the industry.

“Wanda Film’s exploration of diversified businesses is accelerating in practice. In June this year, we further evolved our Super Entertainment Space strategy into a new ‘1+2+5’ blueprint, with the ‘2’ referring to the domestic and international markets. Under this new direction, we aim to broaden our market reach and co-create more opportunities with global partners,” said Chen Zhixi, Chairwoman of Wanda Film. “IMAX has long been one of our most important partners. Beyond elevating content and the viewing experience, this expanded collaboration will see Wanda Film leveraging its venue advantages together with IMAX’s global network to jointly build a new industry ecosystem.”

“The IMAX experience begins on the big screen, but our story doesn’t end there,” said Daniel Manwaring, CEO of IMAX China. “We’re extending the hallmark feature of IMAX into more consumer touchpoints. As IMAX’s largest exhibition partner worldwide, Wanda Film brings invaluable local insight and operational excellence to this effort. Together, we are taking a pivotal step forward in building a broader ecosystem – one that grows sustainably beyond the theatrical experience and engages an even wider spectrum of consumers.”

As an effort to attract younger audiences and expand the influence of IMAX’s brand equity beyond the big screen into a broader range of lifestyle contexts, IMAX has accelerated cross-industry collaborations that extend its presence beyond traditional moviegoing. Earlier this year, IMAX partnered with Razer on co-branded keycaps and mouse peripherals, bringing the IMAX DNA into creative, gaming, and esports environments and establishing a scalable model for future merchandise initiatives.

About Wanda Film

Wanda Film is China’s leading film and entertainment company and a key force shaping the country’s evolving theatrical and content landscape. Guided by its strategic vision of building a “super entertainment space,” the company operates across five major business pillars — cinema exhibition, film and TV production, strategic investments, licensed merchandise and collectibles, and gaming — driving synergies across the entire entertainment value chain.

As China’s largest cinema operator, Wanda Film has ranked No. 1 nationwide in box office revenue, admissions, and market share for sixteen consecutive years. Its footprint extends beyond China through HOYTS, which consistently ranks among the top exhibitors in Australia and New Zealand, further strengthening Wanda Film’s international presence.

In content production, Wanda Film has produced and released nearly 200 titles to date, reaching a cumulative global box office of over RMB 100 billion. The company continues to build a robust, IP-driven content ecosystem, with a strong focus on creative excellence, high-quality production, and talent development.

Wanda Film also advances strategic investments that complement its core businesses and create new momentum for long-term growth. Its consumer products arm, Rtime, develops licensed merchandise, art collectibles and lifestyle products, combining original IP incubation with top-tier global licensing partnerships. Through its proprietary Rtime Link digital certification platform, the company integrates physical collectibles with digital assets, enabling innovative, data-driven rights management.

In gaming, Wanda Film is expanding the boundaries of entertainment by creating deeper connections between games and film IP, fostering a co-creative ecosystem rather than a one-directional licensing model.

Looking ahead, Wanda Film will continue to advance its “super entertainment space” strategy, leveraging technology and innovation to build a more dynamic, diversified and high-quality entertainment landscape for audiences in China and around the world.

About IMAX China

IMAX China is a subsidiary of IMAX Corporation and was incorporated as a limited liability company under the laws of Cayman Islands. IMAX China was established by IMAX Corporation specifically to oversee the expansion of IMAX’s business throughout Greater China. Shares of IMAX China trade on the Hong Kong Stock Exchange under the stock code “1970”.

About IMAX Corporation

IMAX, an innovator in entertainment technology, combines proprietary software, architecture, and equipment to create experiences that take you beyond the edge of your seat to a world you’ve never imagined. Top filmmakers and studios are utilizing IMAX systems to connect with audiences in extraordinary ways, making IMAX’s network among the most important and successful theatrical distribution platforms for major event films around the globe.

IMAX is headquartered in New York, Toronto and Los Angeles, with additional offices in London, Dublin, Tokyo and Shanghai. As of September 30, 2025, there were 1,829 IMAX systems (1,759 commercial multiplexes, 10 commercial destinations and 60 institutional locations) operating in 89 countries and territories. Shares of IMAX China Holding, Inc., a subsidiary of IMAX Corporation, trade on the Hong Kong Stock Exchange under the stock code “1970.”

IMAX®, IMAX 3D®, Experience It In IMAX®, The IMAX Experience®, DMR®, Filmed For IMAX®, IMAX Live®, IMAX Enhanced® and IMAX StreamSmart™ are trademarks and trade names of the Company or its subsidiaries that are registered or otherwise protected under laws of various jurisdictions. For more information, visit www.imax.com. You can also connect with IMAX on Instagram (www.instagram.com/company/imax), Facebook (www.facebook.com/imax), LinkedIn (www.linkedin.com/company/imax), X (www.twitter.com/imax), and YouTube (www.youtube.com/imaxmovies).

SAN FRANCISCO and SUZHOU, China, Dec. 5, 2025 /PRNewswire/ — Innovent Biologics (HKEX: 01801) today announced that the global strategic collaboration with Takeda (TSE: 4502, NYSE: TAK) has closed and become effective following the satisfaction of all closing conditions. The collaboration, initially announced on October 22, 2025, aims to accelerate the global development and commercialization of Innovent’s next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies, including the global partnership on IBI363 (PD-1/IL-2^α-bias) and IBI343 (CLDN18.2 ADC), and an option for an early-stage program IBI3001 (EGFR/B7H3 ADC).

Dr. Hui Zhou, Chief R&D Officer for Oncology Pipeline at Innovent, stated, “IBI363 and IBI343 represent our next-generation therapies designed to address critical unmet needs in global cancer treatment. With clear, aligned development plans, Innovent’s deep understanding of these assets, combined with Takeda’s extensive experience and strong development and commercialization capabilities, we are poised to maximize the clinical potential of these assets across multiple indications. We look forward to the collaboration with our partner going forward.”

Under the agreement:

• Innovent and Takeda will co-develop IBI363 globally, and co-commercialize IBI363 in the U.S., with Takeda leading the co-development and co-commercialization efforts under joint governance and aligned development plan. In addition, Innovent has granted Takeda exclusive commercialization rights for IBI363 outside Greater China and the U.S. Takeda has global manufacturing rights to supply IBI363 outside of Greater China, with such rights being co-exclusive with Innovent for commercial supply in the U.S.
• Innovent has also granted Takeda exclusive global rights to develop, manufacture and commercialize IBI343 outside of Greater China.
• Additionally, Takeda receives an exclusive option to license global rights for IBI3001, a first-in-class EGFR/B7H3 bispecific ADC in Phase 1 stage, outside Greater China.

Takeda will pay Innovent an upfront payment of US$1.2 billion, including a US$100 million equity investment in Innovent through new share issuance at premium, i.e., HK$112.56 per share. Furthermore, Innovent is eligible for development and sales milestone payments for IBI363, IBI343, and IBI3001 (if option exercised) totaling up to approximately $10.2 billion, for a total deal value of up to $11.4 billion. Innovent is also eligible to receive potential royalty payments for each molecule outside Greater China, except with respect to IBI363 in the U.S., where the parties will share profits or losses (40/60 Innovent/Takeda).

Detailed information about the collaboration can be found at the official website of Innovent Biologics.

About Innovent Biologics

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 17 products in the market. It has 1 new drug applications under regulatory review, 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Forward-looking statement

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.